Product Description
An orally bioavailable 2-phenylaminopyrimidine derivative with potential antineoplastic activity. Bafetinib specifically binds to and inhibits the Bcr/Abl fusion protein tyrosine kinase, an abnormal enzyme produced by Philadelphia chromosomal translocation associated with chronic myeloid leukemia (CML). (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bafetinib)
Mechanisms of Action: Bcr-Abl Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CytRx
Company Location: LOS ANGELES CA 90049
Company CEO: Stephen Snowdy
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia
Phase 1: Chronic Lymphoid Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myeloid Leukemia|Astrocytoma|Ependymoma|Glioblastoma|Oligodendroglioma|Brain Cancer|Giant Cell Tumors|Gliosarcoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BAFETINIB-P1-GBM-01 | P1 |
Completed |
Glioblastoma|Brain Cancer|Astrocytoma|Gliosarcoma|Oligodendroglioma|Ependymoma|Giant Cell Tumors |
2013-03-01 |
|
| BAFETINIB-P2-CLL-01 | P2 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2011-12-01 |
|
| PROACT | P2 |
Completed |
Prostate Cancer |
2011-09-01 |
|
| INNO-406 | P1 |
Completed |
Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia |
2008-05-01 |